Crcm LP Sells 209,329 Shares of Burning Rock Biotech Limited Sponsored ADR $BNR

Crcm LP decreased its position in Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR) by 42.6% in the first quarter, Holdings Channel reports. The institutional investor owned 282,097 shares of the company’s stock after selling 209,329 shares during the period. Burning Rock Biotech accounts for about 3.3% of Crcm LP’s portfolio, making the stock its 4th largest position. Crcm LP’s holdings in Burning Rock Biotech were worth $4,601,000 at the end of the most recent quarter.

Separately, Prospera Financial Services Inc boosted its stake in shares of Burning Rock Biotech by 26.0% during the 4th quarter. Prospera Financial Services Inc now owns 31,185 shares of the company’s stock worth $628,000 after acquiring an additional 6,430 shares in the last quarter. 30.03% of the stock is currently owned by hedge funds and other institutional investors.

Burning Rock Biotech Price Performance

Burning Rock Biotech stock opened at $9.14 on Thursday. The company’s fifty day moving average price is $10.47 and its 200 day moving average price is $19.04. Burning Rock Biotech Limited Sponsored ADR has a 1 year low of $5.31 and a 1 year high of $41.72. The stock has a market capitalization of $96.15 million, a P/E ratio of -11.15 and a beta of 1.32. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.81 and a current ratio of 3.05.

Burning Rock Biotech (NASDAQ:BNR) last posted its quarterly earnings data on Tuesday, June 9th. The company reported ($0.20) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.29) by $2.09. The company had revenue of $15.66 million during the quarter, compared to analysts’ expectations of $19.21 million. Burning Rock Biotech had a negative net margin of 11.57% and a negative return on equity of 10.98%.

Insider Activity

In related news, Director Yusheng Han bought 24,900 shares of the business’s stock in a transaction dated Friday, June 26th. The stock was acquired at an average price of $8.00 per share, with a total value of $199,200.00. Following the completion of the purchase, the director directly owned 18,404,086 shares of the company’s stock, valued at approximately $147,232,688. This trade represents a 0.14% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders have bought a total of 731,410 shares of company stock valued at $6,182,660 in the last quarter. 30.30% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on BNR shares. Weiss Ratings restated a “sell (d-)” rating on shares of Burning Rock Biotech in a research report on Friday, July 17th. Wall Street Zen cut Burning Rock Biotech from a “buy” rating to a “hold” rating in a report on Saturday, June 13th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Burning Rock Biotech currently has a consensus rating of “Sell”.

Burning Rock Biotech Profile

Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.